chartexchange

Amneal Pharmaceuticals Reports Q3 2026 Revenue of $863 Million, Adjusted EPS of $0. ...

GuruFocus | Nov 3, 2026 8:34 AM EST

Revenue grows 10% as Affordable Medicines and Specialty segments post double-digit gains; full-year guidance raised again Related Stocks: AMRX ,

Read original article